Inconsistencies in 2022 ISPD peritonitis guidelines

Abstract

Get full access to this article

View all access options for this article.

References

Chow

Cho

, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42: 110–153.

Peerapornratana

Chariyavilaskul

Kanjanabuch

, et al. Short-dwell cycling intraperitoneal cefazolin plus ceftazidime in peritoneal dialysis patients. Perit Dial Int 2017; 37: 218–224.

Lam

Tang

BSF

Chan

, et al. Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. Perit Dial Int 2008; 28: 540–542.

Fitzpatrick

Esterly

Postelnick

, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal Polymixin B and ampicillin-sulbactam. Ann Pharmacother 2012; 46: e17.

Piraino

Bailie

Bernardini

, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107–131.

Szeto

Piraino

, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30: 393–423.

Szeto

Piraino

, et al. ISPD peritonitis recommendations: 2016 update on Prevention and treatment. Perit Dial Int 2016; 36: 481–508.

Lam

Lien

YTK

Kraft

, et al. Vancomycin in peritoneal dialysis: clinical pharmacology considerations in therapy. Perit Dial Int 2020; 40: 384–393.

Lam

Lien

Kraft

, et al. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clin Transl Sci 15(3): 649–657. DOI: 10.1111/cts.13182.